1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Zoetis Inc.

Zoetis Inc.

ZTS
Zoetis Inc.US flagNew York Stock Exchange
71.45
USD
-1.57
- -
29.95BMarket Cap
Zoetis Inc.
ZTS
(New York Stock Exchange)

Recent

price

71.45

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
7.49
8.85
8.67
9.12
9.55
9.54
9.86
10.83
12.06
13.09
14.04
16.39
17.23
18.53
20.38
21.35
22.12
Revenue per Share
0.23
0.51
0.87
1.01
1.16
0.68
1.66
1.76
2.96
3.14
3.44
4.29
4.51
5.08
5.47
6.03
6.08
Basic EPS, GAAP
0.27
0.76
0.66
0.99
0.86
0.88
1
2.75
3.71
3.75
4.47
4.67
4.08
5.1
6.5
6.55
6.6
Free Cash Flow per Basic Share
0.43
0.87
0.13
0.2
0.29
0.34
0.38
0.42
0.5
0.66
0.8
1
1.3
1.5
1.73
2
2.07
Dividend per Share
6.69
7.44
8.05
1.88
2.62
2.15
3.02
3.64
4.56
5.69
7.93
9.61
9.5
10.9
10.64
7.84
7.6
Book Value per Share
2.97
3.61
4.35
-1.69
-0.78
-3.17
-2.48
-2.08
-4.96
-3.73
-1.34
0.82
0.6
1.96
2.05
-1.02
-1.31
Tangible Book Value per Share
478
478
500
500
501
500
496
490
483
478
476
474
469
461
454
443
430
Basic Weighted Avg Shares
3,582
4,233
4,336
4,561
4,785
4,765
4,888
5,307
5,825
6,260
6,675
7,776
8,080
8,544
9,256
9,467
9,517
Sales/Revenue/Turnover
8.01
14.93
19.14
17.98
20.25
22.46
28.58
32.5
32.29
32.24
33.99
36.05
36.24
35.92
36.65
38
37.65
Operating Margin (%)
185
205
200
209
204
199
240
242
308
412
441
448
465
491
497
487
482
Depreciation Expense
110
245
436
504
583
339
821
864
1,428
1,500
1,638
2,037
2,114
2,344
2,486
2,673
2,616
Net Income, GAAP
37.64
37.06
38.59
27.1
28.41
37.8
33.31
43.48
15.74
16.71
18.04
18.25
20.52
20.3
20.33
20.45
20.05
Effective Tax Rate (%)
3.07
5.79
10.06
11.05
12.18
7.11
16.8
16.28
24.52
23.96
24.54
26.2
26.16
27.43
26.86
28.23
27.49
Profit Margin (%)
1,308
1,468
1,741
1,942
2,379
2,049
2,273
3,123
3,176
2,942
4,441
5,133
4,339
4,454
2,574
4,533
4,295
Working Capital
673
575
509
3,642
3,624
4,463
4,468
4,953
6,443
6,111
6,758
6,743
6,738
6,752
5,394
9,238
9,238
LT Debt
3,344
3,736
4,041
962
1,337
1,091
1,499
1,786
2,185
2,708
3,773
4,544
4,403
4,991
4,770
3,331
3,148
Total Equity
8.83
9.52
11.45
12.95
14.47
12.16
15.53
15.26
20.55
18.69
18.15
20.4
19.44
19.99
23.07
23.56
23.53
Return on Invested Capital (%)
6.51
6.33
10.19
12.71
13.83
7.62
15.66
15.19
20.88
18.78
17.89
19.83
19.28
20.95
22.83
23.66
23.24
Return on Capital (%)
6.58
6.94
11.26
20.3
51.8
28.5
64.27
53.05
72.21
61.31
50.58
49.01
47.25
49.86
50.91
65.99
64.39
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
9,042
9,045
9,048
LT Finance Leases
196
193
190
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
425
420
414
Market Capitalization
53,464
49,689
29,761

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
6,768
6,474
6,356
Cash, Cash Equivalents & STI
2,310
1,940
1,673
Accounts Receivable, Net
1,590
1,506
1,571
Inventories
2,430
2,550
2,574
Total Current Liabilities
2,235
2,053
2,061
Payables & Accruals
1,718
1,693
1,667
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
13.82%
-0.78%
-30.17%
Free Cash Flow
27.29%
7.48%
-1.66%
Net Income, GAAP
27.95%
10.52%
7.52%
Sales/Revenue/Turnover
7.18%
7.35%
2.28%
Total Cash Common Dividend
18.32%
18.72%
13.1%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,190
2,361
2,388
2,317
9,256
2025
2,198
2,474
2,400
2,387
9,467
2026
2,262
2,468
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.31
1.37
1.51
1.29
5.47
2025
1.34
1.63
1.63
1.38
6.03
2026
1.42
1.65
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.43
0.43
0.43
0.43
1.73
2025
0.5
0.5
0.5
0.5
2
2026
0.53
0.53
- -
- -
- -
Similar Companies
Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (603707.SS)
Bhang Inc. (BHNGF)
Sandoz Group AG (0SAN.L)
Planet 13 Holdings Inc. (PLNHF)
Indivior PLC (INVVY)
Zydus Lifesciences Limited (ZYDUSLIFE.BO)
Business
Zoetis Inc. (NYSE: ZTS) develops, manufactures and commercializes animal health medicines and vaccines, as well as a range of other animal health products and services. The company offers pharmaceuticals including anti-infectives, dermatology products, pain and sedation therapeutics, and reproductive controls; vaccines for livestock and companion animals such as dogs, cats, horses and cattle; and diagnostics, parasiticides, dermatology treatments, medicated topicals, vaccines and therapeutics for small and large animals. Zoetis provides platform technologies like the Zoetis Petcare solutions for pet owners and veterinarians, including telehealth services and data-driven insights, along with contract manufacturing and research services for biopharmaceuticals. Operating in over 100 countries with a primary focus on North America, Europe, and emerging markets in Latin America, Asia and Africa, the company targets veterinarians, livestock producers and pet owners as key customers. Founded in 2012 as a spin-off from Pfizer Inc.'s animal health business and headquartered in Parsippany, New Jersey, Zoetis has no major parent company or significant subsidiaries beyond its global operating units. In recent developments, Zoetis expanded its portfolio through the 2024 launch of new monoclonal antibody therapies for canine osteoarthritis and atopic dermatitis under the Libertym brand, formed a strategic alliance with Pharmgate Animal Health in 2025 for U.S. swine feed antibiotics distribution, and completed the acquisition of Basepaws in 2023 to bolster its pet genetics and diagnostics capabilities, reflecting ongoing innovation and market penetration efforts.

Company News

Company News APIChatGPT

  • seekingalpha.com

    Zoetis: The Worst May Be Priced In

  • marketbeat.com

    Zoetis Stands by Guidance as Pet-Care Weakness and Competition Pressure Sales

  • seekingalpha.com

    Zoetis: An Undervalued Compounder Hiding In Plain Sight

  • seekingalpha.com

    Zoetis Inc. (ZTS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

  • defenseworld.net

    Corient Private Wealth LP Has $35.07 Million Holdings in Zoetis Inc. $ZTS

  • defenseworld.net

    Critical Analysis: Zoetis (NYSE:ZTS) and Urogen Pharma (NASDAQ:URGN)

  • finbold.com

    ‘Big Short' Michael Burry just updated his portfolio for September

  • defenseworld.net

    HB Wealth Management LLC Boosts Holdings in Zoetis Inc. $ZTS

  • businesswire.com

    Zoetis to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

  • seekingalpha.com

    Phibro Animal Health: Zoetis Integrated And Better Cash Flow Ahead

  • defenseworld.net

    Blackhill Capital Inc. Cuts Stock Position in Zoetis Inc. $ZTS

  • fool.com

    3 High-Yielding Dividend Stocks That Have Doubled Their Payouts in 5 Years

  • seekingalpha.com

    Zoetis: A Solid Long-Term Buy After Harsh Drawdown

  • seekingalpha.com

    Zoetis: Another Bad Quarter, Some Value Trap Risk But Shares Still Cheap

  • seekingalpha.com

    Zoetis: The Growth Story Has Broken, But The Valuation Finally Makes Sense

  • businesswire.com

    Zoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and Puppies

  • reuters.com

    Zoetis gets US FDA emergency use nod for treatment for screwworm in dogs

  • defenseworld.net

    Zoetis Q2 Earnings Call Highlights

  • defenseworld.net

    Zoetis (NYSE:ZTS) Hits New 1-Year Low on Analyst Downgrade

  • marketbeat.com

    Zoetis Q2 Earnings Call Highlights